SCHEMBL5906838

SCHEMBL5906838

COC(=O)[C@H](Cc1ccccc1)Nc1cc(-c2ccc(N(Cc3ccccc3)C(=O)OC(C)(C)C)cc2)ncn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.41
CYP3A4 P08684 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 3/20 0.41
MAPT P10636 3/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TP53 P04637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2C9 P11712 1/20 0.41
NPR3 P17342 1/20 0.41
CYP2C19 P33261 1/20 0.41
ITGA4 P13612 2/20 0.40
ITGB7 P26010 1/20 0.40
KLK5 Q9Y337 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5906834 1.00 ADORA2A (0.41) ADORA2ACYP3A4ALDH1A1CYP1A2MAPT
SCHEMBL5906901 0.93 ADORA2A (0.42) ADORA2ACYP3A4ALDH1A1CYP1A2MAPT
SCHEMBL5906905 0.93 ADORA2A (0.42) ADORA2ACYP3A4ALDH1A1CYP1A2MAPT
SCHEMBL5906925 0.82 NPR3 (0.51) CYP3A4MAPTTP53KDM4ECYP2C8
SCHEMBL5906929 0.82 NPR3 (0.51) CYP3A4MAPTTP53KDM4ECYP2C8
SCHEMBL5906837 0.81 TACR3 (0.47) ADORA2ACYP3A4ALDH1A1CYP1A2MAPT
SCHEMBL5906841 0.81 TACR3 (0.47) ADORA2ACYP3A4ALDH1A1CYP1A2MAPT
SCHEMBL5906861 0.81 ELANE (0.48) CYP3A4ALDH1A1CYP1A2MAPTHSD17B10
SCHEMBL5906697 0.81 TACR3 (0.47) ADORA2ACYP3A4ALDH1A1CYP1A2MAPT
SCHEMBL5906767 0.81 ELANE (0.48) CYP3A4ALDH1A1CYP1A2MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089371-A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist BAYER HEALTHCARE AG (DE) 2006-04-27 US disclosed
EP-1575919-A1 PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST Bayer HealthCare AG (DE) 2005-09-21 EP disclosed
WO-2004043926-A1 PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST BAYER HEALTHCARE AG (DE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089371-A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist BPHL, HRH4, HRH2 ADORA2A 454/4885CYP3A4 453/4885ALDH1A1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.